{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:10:39Z","timestamp":1780380639435,"version":"3.54.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Ministry of Health, British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","award":["F16-03294"],"award-info":[{"award-number":["F16-03294"]}],"id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The uptake of hepatitis C virus (HCV) treatment, including among under-served populations, has improved significantly in the Direct Acting Antiviral (DAA) era. However, it is unclear whether patients undergoing HCV treatment are receiving adequate support to engage in healthcare for other concurrent conditions. We sought to characterize psychiatric disorders and depressive symptomatology among a cohort of patients recently treated for HCV. We conducted a secondary analysis using data from the Preservation of Sustained Virologic Response (Per-SVR) study, a prospective cohort of individuals who achieved sustained virologic response (SVR) following DAA treatment in British Columbia, Canada. After confirming SVR through receipt of an undetectable HCV viral load test within three months post-treatment, participants were enrolled in the study and completed interviewer-administered surveys. Logistic regression was used to characterize depressive symptoms and psychiatric diagnoses. Among 256 participants, 122 (48%) had significant depressive symptoms and 142 (55%) reported ever having been diagnosed with a psychiatric disorder. Less than half (44%) of those with depressive symptoms had ever been diagnosed with depressive disorder. Participants with depressive symptoms were more likely to report experiencing recent healthcare barriers (adjusted odds ratio: 2.27; 95% confidence interval: 1.02, 5.03). We observed a high prevalence of psychiatric comorbidity among a cohort of patients recently treated for HCV, highlighting an opportunity to engage HCV patients in mental health care. The integration of mental health screening and treatment alongside HCV care may improve health outcomes among HCV-affected populations.<\/jats:p>","DOI":"10.1371\/journal.pone.0344862","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:28:21Z","timestamp":1773768501000},"page":"e0344862","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond direct-acting antiviral therapy: Characterizing mental health conditions and depressive symptoms among patients recently treated for hepatitis C"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6738-1512","authenticated-orcid":true,"given":"Sarah E.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adedayo","family":"Ajidahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Bytelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio S. G.","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Salters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"pone.0344862.ref001","author":"World Health Organization [Internet]"},{"issue":"12","key":"pone.0344862.ref002","doi-asserted-by":"crossref","first-page":"561","DOI":"10.14745\/ccdr.v47i12a01","article-title":"The hepatitis C epidemic in Canada: an overview of recent trends in surveillance, injection drug use, harm reduction and treatment","volume":"47","author":"L Louren\u00e7o","year":"2021","journal-title":"Can Commun Dis Rep"},{"issue":"2","key":"pone.0344862.ref003","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3138\/canlivj-2022-0029","article-title":"Province-to-province variability in hepatitis C testing, care, and treatment across Canada","volume":"6","author":"E Mandel","year":"2023","journal-title":"Can Liver J"},{"issue":"4","key":"pone.0344862.ref004","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3138\/canlivj.2018-0011","article-title":"Contextualizing Canada\u2019s hepatitis C virus epidemic","volume":"1","author":"M Krajden","year":"2018","journal-title":"Can Liver J"},{"key":"pone.0344862.ref005","author":"The Canadian Network on Hepatitis C [Internet]","year":"2019"},{"key":"pone.0344862.ref006","author":"Pan-Canadian Health Inequalities Reporting Initiative [Internet]"},{"key":"pone.0344862.ref007","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2334-12-86","article-title":"The high comorbidity burden of the hepatitis C virus infected population in the United States","volume":"12","author":"KS Louie","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0344862.ref008","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1186\/s12879-019-4315-6","article-title":"HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study","volume":"19","author":"CL Cooper","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"8","key":"pone.0344862.ref009","article-title":"A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study","volume":"13","author":"DM Evon","year":"2018","journal-title":"PLoS One"},{"key":"pone.0344862.ref010","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.drugpo.2021.103247","article-title":"Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis","volume":"96","author":"A Amoako","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"6","key":"pone.0344862.ref011","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy120","article-title":"Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting","volume":"5","author":"A Alimohammadi","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"pone.0344862.ref012","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/liv.14043","article-title":"Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting","volume":"39","author":"ME Soc\u00edas","year":"2019","journal-title":"Liver Int"},{"issue":"1","key":"pone.0344862.ref013","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12876-022-02416-5","article-title":"Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up","volume":"22","author":"PJ Clark","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"pone.0344862.ref014","doi-asserted-by":"crossref","DOI":"10.1086\/427442","article-title":"Addressing tri\u2010morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care","volume":"40","author":"M Fireman","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0344862.ref015","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/gast.2002.34750","article-title":"Psychiatric disorders among veterans with hepatitis C infection","volume":"123","author":"HB el-Serag","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"pone.0344862.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2022.03.023","article-title":"Mental Illness in Adults With HIV and HCV Infection: Indian Health Service, 2001-2020","volume":"63","author":"CM Smith","year":"2022","journal-title":"Am J Prev Med"},{"issue":"1","key":"pone.0344862.ref017","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/ADM.0000000000000261","article-title":"Depression, anxiety, and stress among people with chronic hepatitis C virus infection and a history of injecting drug use in New South Wales, Australia","volume":"11","author":"E Fortier","year":"2017","journal-title":"J Addict Med"},{"issue":"1","key":"pone.0344862.ref018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.genhosppsych.2007.08.014","article-title":"High frequency of unrecognized mental disorders in HCV-infected patients","volume":"30","author":"SC Batista-Neves","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"pone.0344862.ref019","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","article-title":"Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study","volume":"2","author":"N Islam","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"pone.0344862.ref020","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/liv.14762","article-title":"HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men","volume":"41","author":"PA Adu","year":"2021","journal-title":"Liver Int"},{"key":"pone.0344862.ref021","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","edition":"5"},{"issue":"7","key":"pone.0344862.ref022","article-title":"Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada","volume":"7","author":"W Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"pone.0344862.ref023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/070674370805300105","article-title":"Validation of the alcohol use disorders identification test and the drug abuse screening test in first episode psychosis","volume":"53","author":"CM Cassidy","year":"2008","journal-title":"Can J Psychiatry"},{"key":"pone.0344862.ref024","author":"EuroQol [Internet]"},{"issue":"2","key":"pone.0344862.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031115","article-title":"Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies","volume":"7","author":"N Bansback","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"pone.0344862.ref026","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/QAD.0b013e32811ebf57","article-title":"The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART","volume":"21","author":"VD Lima","year":"2007","journal-title":"AIDS"},{"key":"pone.0344862.ref027","doi-asserted-by":"crossref","first-page":"540","DOI":"10.14745\/ccdr.v48i1112a07","article-title":"National Hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019","volume":"48","author":"N Popovic","year":"2022","journal-title":"Can Commun Dis Rep"},{"key":"pone.0344862.ref028","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa142","article-title":"Psychosocial factors and the care cascade for hepatitis C treatment colocated at a syringe service program","volume":"222","author":"D Winetsky","year":"2020","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0344862.ref029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13011-018-0142-9","article-title":"Major depressive disorder and access to health services among people who use illicit drugs in Vancouver, Canada","volume":"13","author":"T Beaulieu","year":"2018","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"pone.0344862.ref030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10461-017-1757-y","article-title":"The Benefits of Psychosocial Interventions for Mental Health in People Living with HIV: A Systematic Review and Meta-analysis","volume":"22","author":"S van Luenen","year":"2018","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0344862.ref031","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12913-023-09359-x","article-title":"Mapping the effectiveness of integrating mental health in HIV programs: a scoping review","volume":"23","author":"NK Conteh","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"pone.0344862.ref032","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1176\/ps.2010.61.9.885","article-title":"Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness","volume":"61","author":"SD Rosenberg","year":"2010","journal-title":"Psychiatr Serv"},{"issue":"5","key":"pone.0344862.ref033","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/jvh.13487","article-title":"Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care","volume":"28","author":"BL Harney","year":"2021","journal-title":"J Viral Hepat"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:28:29Z","timestamp":1773768509000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344862"}},"subtitle":[],"editor":[{"given":"Riccardo","family":"Nevola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344862","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}